Alternatives to Oral Estrogen Replacement

Baker, Valerie L.

doi:10.1016/s0889-8545(21)00629-x

Cited by 53 publications

(8 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topical estrogen creams or gels are applied directly to the skin, facilitating estrogen absorption and systemic delivery [ 45 ]. These formulations provide dosing flexibility, as they can be adjusted based on individual needs.…”

Section: Estrogen Therapy In Postmenopausal Womenmentioning

confidence: 99%

Beyond hot flashes: Exploring the role of estrogen therapy in postmenopausal women for myocardial infarction prevention and recovery

Choradia,

Bai,

Soni

et al. 2023

Biomol Biomed

View full text Add to dashboard Cite

Myocardial infarction (MI) commonly known as "heart attack" results from the blockage of blood flow to the heart. Postmenopausal women face an elevated risk of MI due to declining estrogen levels, a hormone pivotal in maintaining cardiovascular health. It promotes vasodilation, reduce inflammation, and improves lipid profiles. While estrogen therapy shows promise in mitigating MI risk for postmenopausal woman, its efficacy in prevention and recovery remains a subject of debate. This review provides a critical assessment of existing evidence on estrogen therapy's cardioprotective effects for postmenopausal women. It delves into estrogen's role in vascular function enhancement, inflammation reduction, and lipid metabolism modulation. Additionally, it addresses the various forms of estrogen therapy, administration methods, dosage considerations, safety implications, and associated risks. The review highlights the existing controversies and knowledge gaps related to estrogen therapy for MI prevention. It underscores the urgency for in-depth research to decipher the nexus between estrogen therapy and MI risk, especially concerning primary prevention and specific postmenopausal subgroups. Future studies should investigate optimal formulations, doses, and administration routes of estrogen therapy as well as assess treatment timing and duration. Comparative studies and long-term follow-up are necessary to inform clinical decision-making and improve patient care. Addressing these research gaps will empower clinicians to make more judicious choices about estrogen therapy for MI prevention and recovery in postmenopausal women, aiming for enhanced patient outcomes.

show abstract

Section: Estrogen Therapy In Postmenopausal Womenmentioning

confidence: 99%

Beyond hot flashes: Exploring the role of estrogen therapy in postmenopausal women for myocardial infarction prevention and recovery

Choradia,

Bai,

Soni

et al. 2023

Biomol Biomed

View full text Add to dashboard Cite

show abstract

“…As this route avoids the gut wall and there is no first‐pass hepatic metabolism, 14 the adverse gastrointestinal and hypertensive effects are avoided. Transdermal oestrogen may thus be ideal for women with chronic diseases or for those who take medications that stimulate liver enzymes, 20 as well as for those whose vasomotor symptoms have not responded to oral therapy 21 . Furthermore, transdermal oestrogen does not appear to have an effect on clotting factors, to raise blood pressure, or to have the same adverse hepatobiliary effects as oral oestrogens, 8,10 and is associated with less nausea than oral therapy 21 .…”

Section: Oral and Transdermal Oestrogenmentioning

confidence: 99%

“…Transdermal oestrogen may thus be ideal for women with chronic diseases or for those who take medications that stimulate liver enzymes, 20 as well as for those whose vasomotor symptoms have not responded to oral therapy 21 . Furthermore, transdermal oestrogen does not appear to have an effect on clotting factors, to raise blood pressure, or to have the same adverse hepatobiliary effects as oral oestrogens, 8,10 and is associated with less nausea than oral therapy 21 . For a small number of women with lactose intolerance, oral oestrogen will be unacceptable as all the preparations contain lactose in the tablet formulation.…”

Section: Oral and Transdermal Oestrogenmentioning

confidence: 99%

“…21 Furthermore, transdermal oestrogen does not appear to have an effect on clotting factors, to raise blood pressure, or to have the same adverse hepatobiliary effects as oral oestrogens,8-10 and is associated with less nausea than oral therapy. 21 For a small number of women with lactose intolerance, oral oestrogen will be unacceptable as all the preparations contain lactose in the tablet formulation. Lactose is not a constituent of oestradiol preparations given parenterally.…”

Section: Oral and Transdermal Oestrogenmentioning

confidence: 99%

See 1 more Smart Citation

Current Hormone Replacement Therapy: What Are the Shortcomings? Advances in Delivery

Sturdee

1999

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYThe introduction of transdermal and other parenteral delivery systems has broadened the range of options for hormone replacement therapy (HRT). Oral oestrogen is the most common initial therapy; however, direct absorption of oestradiol via the skin results in an oestradiol‐oestrone ratio similar to that found in the pre‐menopausal state. Both oral and transdermal oestrogen therapy have been shown to be equally effective in relieving climacteric symptoms, and in preventing osteoporosis or modifying some cardiovascular disease risk factors, although transdermal therapy tends to have fewer unwanted effects than oral. Satisfactory circulating oestradiol levels are achieved with skin patches, transdermal gel, or crystalloid oestradiol implants, and adding progestogen to protect the endometrium is well established. Sequential therapy with HRT usually produces a regular bleed, which is a major cause of patient dissatisfaction. The ideal HRT regimen is probably unobtainable, but the development of SERMs and other regimens that avoid bleeding will encourage long‐term use.

show abstract

“…The transdermal dosing route offers several benefits, including the maintenance of a relatively constant circulating drug level, the avoidance of first‐pass hepatic metabolism, reduced frequency of dose administration, and easy initiation, discontinuation, and adjustment of drug therapy 23–25 . It has been suggested by various reviewers that transdermal delivery might be a good alternative for women who prefer not to take oral medications every day, who fail to respond to oral treatment, or who have concomitant conditions that preclude the use of oral ERT 17 , 23 , 26…”

mentioning

confidence: 99%

A RANDOMISED STUDY TO COMPARE THE EFFICACY AND SAFETY OF a NEW 17β‐OESTRADIOL TRANSDERMAL MATRIX PATCH WITH ESTRADERM TTS 50 IN HYSTERECTOMISED POSTMENOPAUSAL WOMEN

Al‐Azzawi

Mooren²,

Rolland³

et al. 1997

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARY This study was designed to compare the efficacy and safety of two sizes of Lyrelle, a new matrix design transdermal oestrogen patch, with Estraderm TTS 50, a reservoir system. Three hundred and ninety‐four (394) hysterectomised postmenopausal women between 30 and 65 years of age participated in this open‐label, randomised, multicentre clinical trial. The main efficacy criterion was the reduction in the mean number of hot flushes per day at six months. Secondary efficacy end points included other climacteric symptoms as well as various psychofunctional and genitourinary disorders. A significant decrease from baseline in the mean number of hot flushes/day was observed in all three groups from the end of cycle 1, reaching 90% at the end of cycle 7. There was no statistically significant difference between Lyrelle 50 and Estraderm at any time point for any parameter; however, between‐group differences between Lyrelle 80 and Estraderm for various parameters were seen in the first three cycles in favour of Lyrelle 80. A similar impact on blood lipid levels was observed in all three groups, without significant between‐group differences. We conclude that the new Lyrelle patch is a highly effective system for transdermal oestrogen replacement therapy that may enhance long‐term patient compliance

show abstract

Alternatives to Oral Estrogen Replacement

Cited by 53 publications

References 102 publications

Beyond hot flashes: Exploring the role of estrogen therapy in postmenopausal women for myocardial infarction prevention and recovery

Beyond hot flashes: Exploring the role of estrogen therapy in postmenopausal women for myocardial infarction prevention and recovery

Current Hormone Replacement Therapy: What Are the Shortcomings? Advances in Delivery

A RANDOMISED STUDY TO COMPARE THE EFFICACY AND SAFETY OF a NEW 17β‐OESTRADIOL TRANSDERMAL MATRIX PATCH WITH ESTRADERM TTS 50 IN HYSTERECTOMISED POSTMENOPAUSAL WOMEN

Contact Info

Product

Resources

About